HCW Biologics Faces Delisting Concerns
Ticker: HCWB · Form: 8-K · Filed: Dec 23, 2024 · CIK: 1828673
Sentiment: bearish
Topics: delisting, compliance, regulatory
TL;DR
HCW Biologics might get delisted, stock could be in trouble.
AI Summary
HCW Biologics Inc. filed an 8-K on December 23, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard as of December 17, 2024. The filing also includes other events and financial statements/exhibits. The company is incorporated in Delaware and its principal executive offices are located in Miramar, Florida.
Why It Matters
This filing indicates potential delisting from an exchange, which could significantly impact the liquidity and valuation of HCW Biologics Inc. stock.
Risk Assessment
Risk Level: high — A notice of delisting directly threatens the company's ability to remain publicly traded, posing a significant risk to investors.
Key Numbers
- 001-40591 — Commission File Number (Identifies the company's SEC filings)
- 82-5024477 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- HCW Biologics Inc. (company) — Registrant
- December 17, 2024 (date) — Date of earliest event reported
- December 23, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Miramar, Florida (location) — Principal executive offices
FAQ
What specific listing rule or standard has HCW Biologics Inc. failed to satisfy?
The filing indicates a 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard' but does not specify the exact rule in the provided text.
What is the exact date of the event triggering the delisting notice?
The earliest event reported is dated December 17, 2024.
What is the primary business of HCW Biologics Inc. according to its SIC code?
The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Where are HCW Biologics Inc.'s principal executive offices located?
The principal executive offices are located at 2929 N. Commerce Parkway, Miramar, Florida 33025.
What is the Commission File Number for HCW Biologics Inc.?
The Commission File Number is 001-40591.
Filing Stats: 1,080 words · 4 min read · ~4 pages · Grade level 13.4 · Accepted 2024-12-23 08:30:10
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share HCWB The Nasdaq Stock Mar
- $50,000,000 M — ed securities ("MVLS") closed below the $50,000,000 MVLS threshold required for continued lis
Filing Documents
- hcwb-20241217.htm (8-K) — 45KB
- hcwb-ex99_1.htm (EX-99.1) — 13KB
- img90053791_0.jpg (GRAPHIC) — 46KB
- 0000950170-24-139288.txt ( ) — 238KB
- hcwb-20241217.xsd (EX-101.SCH) — 24KB
- hcwb-20241217_htm.xml (XML) — 5KB
01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on June 20, 2024, HCW Biologics Inc. (the "Company") received written notice from the Listing Qualifications Staff ("Staff") of the Nasdaq Stock Market LLC ("Nasdaq") which notified the Company that, for the 30 consecutive business days ended June 17, 2024, the Company's market value of listed securities ("MVLS") closed below the $50,000,000 MVLS threshold required for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(b)(3)(A) (the "MVLS Rule"). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company was provided a compliance period of 180 calendar days in which to regain compliance with the MVLS continued listing requirement, or until December 16, 2024 (the "Compliance Date"). The Company did not regain compliance with the MVLS Rule by December 16, 2024 and, accordingly, by letter dated December 17, 2024, the Staff notified the Company that its securities were subject to delisting from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearing Panel (the "Panel"). The Company plans to timely request a hearing before the Panel, which request will stay any further action by Nasdaq pending the hearing and the expiration of any extension that may be granted to the Company following the hearing. At the hearing, the Company will present its plan to evidence compliance with all applicable listing criteria, including the MVLS Rule, and request an extension of time to do so. The Panel has the authority to grant the Company an extension of up to 180 days from the date of the Staff's delist determination. The Company is considering all options available to it to regain compliance with the MVLS Rule; however, there can be no assurance that the Panel will grant the Company's request for continued listing or that the Company will be able to evidence compliance within the period of time
01 Other Events
Item 8.01 Other Events. Pursuant to applicable Nasdaq Rules, the Company issued a press release on December 23, 2024 announcing receipt of the Nasdaq letter, the Rules upon which it was based, and a description of each specific basis and concern identified by Nasdaq in the letter. A copy of the press release is filed herewith as Exhibit 99.1. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Current Report on Form 8-K ("Form 8-K") contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the Company's intent to request a hearing before a Panel and the Company's expectations regarding how long it may remain listed on The Nasdaq Global Market. The Company's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, including the risk that the Company may not be successful in its appeal to a Panel, the risk that the Company may not otherwise meet the requirements for continued listing under the Nasdaq Listing Rules, the risk that Nasdaq may not grant the Company relief from delisting if necessary, and the risk that the Company may not ultimately meet applicable Nasdaq requirements if any such relief is necessary, among other risks and uncertainties. These and other important factors discussed under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 filed with the U.S. Securities and Exchange Commission ("SEC"), and the Company's other filings with the SEC, including the Company's Quarterly Report on Form 10-Q for the period ended September 30, 2024, could cause actual results to differ materially from those indicated by the forward-looking statements
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated December 23, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HCW BIOLOGICS INC. Date: December 23, 2024 By: /s/ Hing C. Wong Hing C. Wong, Founder and Chief Executive Officer